Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lenalidomide
Drug ID BADD_D01253
Description Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.[A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity.[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.[L16028] Lenalidomide is available only under a special restricted distribution program.[A228708]
Indications and Usage Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Marketing Status Prescription
ATC Code L04AX04
DrugBank ID DB00480
KEGG ID D04687
MeSH ID D000077269
PubChem ID 216326
TTD Drug ID D0Q5NX
NDC Product Code 59572-415; 59572-402; 55488-0700; 0480-1242; 0480-1244; 14096-131; 65727-084; 0480-1246; 59572-420; 59116-4710; 59572-425; 53104-7720; 59572-410; 55111-911; 68554-0090; 71796-026; 0480-1243; 46708-927; 59572-405; 53104-7726; 54893-0061; 82245-0101; 65015-772
Synonyms Lenalidomide | 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)- | IMiD3 Cpd | CC 5013 | CC5013 | CC-5013 | Revlimid | Revimid
Chemical Information
Molecular Formula C13H13N3O3
CAS Registry Number 191732-72-6
SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute graft versus host disease in intestine10.02.01.051; 07.11.01.019; 12.02.09.0200.001158%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.012--Not Available
Chikungunya virus infection11.05.21.0010.000755%Not Available
Oral mucosal erythema07.05.05.0230.003474%Not Available
Quality of life decreased13.18.01.013--Not Available
Heart valve incompetence02.07.02.0030.002895%Not Available
Refractory cytopenia with multilineage dysplasia16.01.04.009; 01.10.04.0090.001158%Not Available
Gastroenteritis norovirus11.05.22.001; 07.19.03.0170.004053%Not Available
Gastrointestinal bacterial infection11.02.01.040; 07.19.02.0170.001737%Not Available
Hepatitis B DNA increased13.08.03.0190.002316%Not Available
5q minus syndrome16.01.04.008; 01.10.04.0080.006344%Not Available
Gastrointestinal viral infection11.05.04.016; 07.19.02.0110.005211%Not Available
Acquired gene mutation08.01.10.002--Not Available
Clostridium test positive13.08.01.007--Not Available
Klebsiella test positive13.08.01.0110.001158%Not Available
Hepatitis C virus test positive13.08.03.0240.001158%Not Available
Pubis fracture15.08.06.004; 12.04.06.0040.002895%Not Available
Refractory cancer16.16.01.0160.001158%Not Available
Cerebral small vessel ischaemic disease24.04.06.034; 17.08.02.0200.001158%Not Available
Bone deformity15.10.03.0060.001158%Not Available
Seizure like phenomena17.12.03.030--Not Available
Human chorionic gonadotropin abnormal13.10.05.0220.004053%Not Available
Human chorionic gonadotropin increased13.10.05.0240.092060%Not Available
Neuroendocrine carcinoma metastatic16.24.01.008; 05.08.01.0120.001158%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.030--Not Available
Skin wound23.03.11.022; 12.01.06.0150.003474%Not Available
Enzyme level increased13.04.02.0150.002316%Not Available
Protein deficiency14.03.02.0230.001158%Not Available
Meniscus injury15.07.03.006; 12.04.03.008--Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.011001%Not Available
The 69th Page    First    Pre   69 70    Next   Last    Total 70 Pages